



**Companies**

Licensor  
 Licensee

**Potential Use**

Disease Area  
 Indication

**Deal Financials**

Potential Deal Size  
 Upfront  
 Milestones Total  
 Milestones Regulatory  
 Milestones Sales

Research Funding  
 Profit Sharing Licensor  
 Profit Sharing Licensee  
 Royalties  
 Equity

**Compound**

Compound Details  
 Compound Name  
 Development Stage

Territory  
 Year of Deal Establishment  
 Free Text Search

**Filter Specification**

73

OR

No.	Licensor	Potential Deal Size (mln) Amount	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln) Remarks	Milestones regulatory (mln) Amount	Milestones sales (mln) Remarks	Milestones sales (mln) Amount	Research Funding (mln) Remarks	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	
060	Alizyme	-		2		40	start F III Japan	3		-		0		0	0	Do
061	Arena Pharmaceuticals	600		17.5	per compound	295	132.5 1st indication; 62.5 2nd indication	195		100		-		0	0	Do
062	Flamel Technologies	165		20		145		-		-		0		0	0	Do
063	Biocompatibles International (CellMed)	-		25		293.5		37.5		256		-		0	0	Sir mit